Micro-X Ltd. · ASX:MX1
Micro-X — Bell Potter Healthcare Conference 2023
20 slides from Micro-X's conference presentation, Nov 14, 2023
Slide 1: Investor Presentation
I N V E S T O R P R E S E N TAT I O N Relentless pursuit of commercial outcomes Bell Potter Healthcare Conference 14 – 16 November 2023 Bell Potter Healthcare Conference I 1
Slide 2: Important Notice
I M P O RTA N T N OT I C E S C O P E & L I M I T A T I O N S This Presentation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company’s assets and liabilities, financial position and perfo
Slide 3: Creating Revolutionary Imaging to Better Lives
C R E AT I N G R E V O L U T I O N A R Y I M A G I N G TO BETTER LIVES Commercialisation I Te c h n o l o g y I People Bell Potter Healthcare Conference I 3
Slide 4: The Future of X-Ray
T H E F U T U R E O F X - R AY Smaller, lighter, reliable Lighter Micro-X Proprietary CNT technology - carbon nanotube emitter made of No heat millions of nanotubes emitting digitally controlled electrons - generate high quality x-ray images Fast pulse Smaller Nano Electronic X-ray Technology Long l
Slide 5: Four Innovative Products
F O U R I N N O VAT I V E P R O D U C T S Each product drives a different utilisation of Micro-X’s world leading technology Mobile Digital Radiology Argus X-ray Camera Checkpoints & Baggage Scanner Brain CT Lightweight and ultra-mobile x-ray World first high-definition bomb imaging Baggage scanner f
Slide 6: Our Strategy
O U R S T R AT E G Y Creating a profitable business with our world class technology 01 02 03 Commercial skills Sweat the asset Target larger and - Commercially driven - Leverage our technology less competitive markets Building commercial skills - prioritising commercial Created significant value in
Slide 7: Reduced & Aligned Cost Base
REDUCED & ALIGNED COST BASE Reduction in unfunded activities and building new commercial partnerships Total Cost Base Unfunded Cost Base Improving the mix of Funded development * Reducing the unfunded cost base* $20m $18.7m $17.9m 4.3m 9.6m $15m $5.4m $5.9m FY22: FY23: FY24: $12.1m 12.1m Reduced $23
Slide 8: 2024 – Recent Progress
2024 – RECENT PROGRESS New leadership delivering on strategic objectives $2.9m sales Q1 [FY23 $3.8m] Argus pipeline $21m DHS contract ext. More focused approach to customers and Multiple customer engagements and US Dept of Homeland Security for Airport delivery into new segments – elite US sports de
Slide 9: Product Portfolio
PRODUCT PORTFOLIO L e v e r a g i n g p r o p r i e t a r y N E X Te c h n o l o g y
Slide 10: Mobile DR
MOBILE DR First product to market validating revolutionary technology Distinct product advantages and range of uses → Smaller, more mobile, full range of imaging applications → Meets hospital mobile imaging requirements and military needs → Applications in elite sports and veterinary clinics Multi-c
Slide 11: Argus X-Ray Camera
A R G U S X - R AY C A M E R A Saving lives by redefining bomb detection Unique product advantages and range → Stand-off detection of potential bomb threats or IEDs – removes operator from threat → One sided imaging enables imaging of otherwise inaccessible targets → Only robot deployable system to
Slide 12: Checkpoints
CHECKPOINTS Next generation self-service security screening Significant advantages for travellers + airports → Faster – Passenger screening in 30 seconds, 8 passengers screened simultaneously. → Safer – Passenger, baggage, and Identification combined with AI to increase detection and reduce false al
Slide 13: Brain CT
BRAIN CT Taking stroke diagnosis from the hospital to the ambulance Saving lives with stroke diagnosis in any ambulance → Mobile – 70kg unit suitable for all road and air ambulances → Accurate – 8 second scan for 3D imaging down to 2ml blood → Enabler – Life saving response time → Economical – impro
Slide 14: Driving Commercial Success
DRIVING COMMERCIAL SUCCESS B u i l d i n g a b u s i n e s s n o t j u s t a t e c h n o l o g y
Slide 15: Revenue Timeline
REVENUE TIMELINE Commercialising four revenue generating product lines by 2026 Revenue Timeline Division Sector Products Commercial Status 2023 2024 2025 2026 Next major milestone $3.8m Revenue – FY23 CE Mark Mobile DR Healthcare FDA and TGA Sales in Europe Sales in Europe 350+ units sold to date Ro
Slide 16: Partners for Growth
PA R T N E R S F O R G R O W T H De-risking development and unlocking value from our Technology Development Partner Development Partner Licensing Partner Leading technology Checkpoints - $28m funding Brain CT - $8m funding Multibeam Emitters - $15m Transform the passenger security Taking stroke diag
Slide 17: Experienced Leadership
EXPERIENCED LEADERSHIP Commercially focused to accelerate growth Ilona Meyer, Non Exec Patrick O'Brien , Non Exec General Counsel Nuix, former Boehringer Former Director Macquarie Group, Ingelheim, Resmed, Medtronic McKinsey and Minter Ellison Kingsley Hall – Chief Executive David Knox – Non-Exec Ch
Slide 18: Corporate & Financials
C O R P O R AT E & FINANCIALS FINANCIALS & SHAREHOLDERS SHARE CAPITAL (1 November 2023) ~A$1.3m (30 September 2023) Cash Share price $0.14 per share Committed cash inflows + $7.2m received October 2023 - $7.2m cash received in October Revenue A$15.0m (FY2023) +67% Total shares on issue 518.1 million
Slide 19: Summary
S U M M A RY Pioneers in carbon nanotube x-ray technology Creating revolutionary imaging to better lives → Pioneers in proprietary carbon nanotube X-ray technology – Nano Electronic X-ray (NEX) → Innovative product portfolio spanning healthcare and security applications Platform technology underpinn
Slide 20: Thank You
ACN 153 273 735 / ASX: MX1 THANK YOU Bell Potter Healthcare Conference I 20